TITLE

Effects of doxorubicin on reproductive system in animal model

AUTHOR(S)
Heidari, M.
PUB. DATE
June 2014
SOURCE
Iranian Journal of Reproductive Medicine;Jun2014 Supplement, Vol. 12, p101
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Introduction: Doxorubicin is a chemotherapeutic agent that used for the treatment some leukemias and Hodgkin's lymphoma, bladder, stomach, lung, and others. The aim of this study was to investigate the effect of cytotoxic events in the reproductive system caused by a single dose of doxorubicin. Materials and Methods: In this experimental study 30 male wistar rats were selected and randomly divided into two groups. Experiment groups were received 2.5 mg/kg and control groups just received normal saline for 60 days. Results: Results showed that doxorubicine had destructive effects on testis tissue and spermatogenesis in test group compared to control group within 60 days after administration, significant decrease in the weight of reproductive organs as compared to control animals. The sperm motility and count in cauda epidydimides, testicular ducts were significantly decreased. Spermatogenesis was decrease at primary and secondary spermatocyte stages and then diameter of seminiferous tubules, thickness of interstitial tissue, and thickness of testicular capsule, were studied. Diameter of seminiferous tubules and thickness of epithelium of seminiferous tubules significantly decreased, but thickness of interstitial tissue and thickness of testicular significant increased compared to controls (p<0.05). Conclusion: Generally doxorubicine administration causes decline in spermatogenesis and significant changes in diameter of seminiferous tubules, thickness of interstitial tissue, and thickness of testicular capsule in rat testis tissue. These changes may via the reducing of cell divide and toxic effects of doxorubicine.
ACCESSION #
96841736

 

Related Articles

  • Doxorubicin liposomal.  // Reactions Weekly;2/4/2012, Issue 1387, p17 

    The article describes the case of a 37-year-old man developed palmoplantar erythrodysaesthesia (PPE) while receiving pegylated (PLD) and non-pegylated doxorubicin (NPLD) liposomal for Hodgkin's disease.

  • Four-cycle ABVD more toxic for older patients with Hodgkin's lymphoma.  // Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p31 

    The article discusses the findings of a study which revealed a significant dose reduction, delay in treatment, toxicity and treatment-associated mortality among patients aged at least 60 years with early-stage Hodgkins lymphoma who took four cycles of treatment with doxorubicin, bleomycin,...

  • Research & Markets: Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma).  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p77 

    The article discusses the need for drugs with enhanced toxicity and efficacy in treating Hodgkin and non-Hodgkin lymphoma. It says that the relapse rate for Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) patients are 30% and 50%. It mentions the report "Brentuximab Vedotin: First...

  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkins lymphoma: CALGB 59804. NL Bartlett; D Niedzwiecki; JL Johnson; JW Friedberg; KB Johnson; K van Besien; AD Zelenetz; BD Cheson; GP Canellos; For the Cancer Leukemia Group B // Annals of Oncology;Jun2007, Vol. 18 Issue 6, p1071 

    Background: Because of high single-agent activity and modest toxicity, we hypothesized the combination of gemcitabine (G), vinorelbine (V), and pegylated liposomal doxorubicin (D) would be an effective salvage therapy for Hodgkins lymphoma (HL). Patients and methods: A total of 91 patients...

  • Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. Diehl, Volker; Franklin, Jeremy; Pfreundschuh, Michael; Lathan, Bernd; Paulus, Ursula; Hasenclever, Dirk; Tesch, Hans; Herrmann, Richard; Dorken, Bernd; Müller-Hermelink, Hans-Konrad; Dühmke, Eckhardt; Loeffler, Markus // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2386 

    Background: Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. Methods: From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or...

  • Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. Aleman, Berthe M.P.; Raemaekers, John M.M.; Tirelli, Umberto; Bortolus, Roberto; van 't Veer, Mars B.; Lybeert, Marnix L.M.; Keuning, Jo J.; Carde, Patrice; Girinsky, Théodore; van der Maazen, Richard W.M.; Tomšič, Radka; Vovk, Marjeta; van Hoof, Achilles; Demeestere, Geertrui; Lugtenburg, Pieternella J.; Thomas, José; Schroyens, Wilfried; De Boeck, Koenraad; Baars, Johanna W.; Kluin-Nelemans, Johanna C. // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2396 

    Background: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial. Methods: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with...

  • Cancer Chemotherapy Update. Solimando Jr., Dominic A.; Waddell, Aubrey // Hospital Pharmacy;Oct2009, Vol. 44 Issue 10, p858 

    The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and...

  • The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use. Kaufman, Gregory P.; Ristow, Kay M.; Markovic, Svetomir N.; Porrata, Luis F. // Blood & Lymphatic Cancer: Targets & Therapy;2014, Vol. 4, p39 

    Risk stratification of patients with classical Hodgkin lymphoma (cHL) remains suboptimal. The ratio of the absolute lymphocyte count (ALC) to absolute monocyte count (AMC) both at diagnosis and during subsequent recovery from serial cycles of chemotherapy predicts survival in cHL, and possesses...

  • Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report. Hughes, Caren L.; Yorio, Jeffrey T.; Kovitz, Craig; Oki, Yasuhiro // Journal of Medical Case Reports;2014, Vol. 8 Issue 1, p567 

    Introduction Guillain-Barre syndrome, or acute inflammatory demyelinating polyneuropathy, has been described in the presence of malignancies such as lymphoma. Guillain-Barre syndrome/acute inflammatory demyelinating polyneuropathy causes paresthesias and weakness, which can make the treatment of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics